These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 6159502)

  • 21. A multimodality therapeutic approach in anaplastic thyroid carcinoma: study on 39 patients.
    Busnardo B; Daniele O; Pelizzo MR; Mazzarotto R; Nacamulli D; Devido D; Mian C; Girelli ME
    J Endocrinol Invest; 2000 Dec; 23(11):755-61. PubMed ID: 11194710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemotherapy of thyroid carcinoma.
    Ahuja S; Ernst H
    J Endocrinol Invest; 1987 Jun; 10(3):303-10. PubMed ID: 3624802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anaplastic thyroid carcinoma: comparison of conventional radiotherapy and hyperfractionation chemoradiotherapy in two groups.
    Heron DE; Karimpour S; Grigsby PW
    Am J Clin Oncol; 2002 Oct; 25(5):442-6. PubMed ID: 12393980
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of combined radioimmunotherapy and chemotherapy for treatment of medullary thyroid cancer.
    Stein R; Juweid M; Zhang CH; Goldenberg DM
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3199s-3206s. PubMed ID: 10541364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
    Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
    Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents.
    Chen G; Xu S; Renko K; Derwahl M
    J Clin Endocrinol Metab; 2012 Apr; 97(4):E510-20. PubMed ID: 22278418
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells.
    Catalano MG; Fortunati N; Pugliese M; Poli R; Bosco O; Mastrocola R; Aragno M; Boccuzzi G
    J Endocrinol; 2006 Nov; 191(2):465-72. PubMed ID: 17088416
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alginate/Carboxymethyl Chitosan Core-Shell Microspheres Coloaded with Doxorubicin/Docetaxel Reverse Chemotherapy Resistance in Anaplastic Thyroid Carcinoma.
    Zhou Y; Yang F; Zhou H; Lv S
    Thyroid; 2024 Jul; 34(7):856-870. PubMed ID: 38661518
    [No Abstract]   [Full Text] [Related]  

  • 29. Combined doxorubicin, hyperfractionated radiotherapy, and surgery in anaplastic thyroid carcinoma. Report on two protocols. The Swedish Anaplastic Thyroid Cancer Group.
    Tennvall J; Lundell G; Hallquist A; Wahlberg P; Wallin G; Tibblin S
    Cancer; 1994 Aug; 74(4):1348-54. PubMed ID: 8055459
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anaplastic and poorly differentiated thyroid carcinoma: therapeutic strategies and treatment outcome of 52 consecutive patients.
    Siironen P; Hagström J; Mäenpää HO; Louhimo J; Heikkilä A; Heiskanen I; Arola J; Haglund C
    Oncology; 2010; 79(5-6):400-8. PubMed ID: 21455012
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemotherapy of skeletal metastases.
    Cadman E; Bertino JR
    Int J Radiat Oncol Biol Phys; 1976; 1(11-12):1211-5. PubMed ID: 62744
    [No Abstract]   [Full Text] [Related]  

  • 32. Update on thyroid cancer treatment.
    Regalbuto C; Frasca F; Pellegriti G; Malandrino P; Marturano I; Di Carlo I; Pezzino V
    Future Oncol; 2012 Oct; 8(10):1331-48. PubMed ID: 23130931
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytotoxic chemotherapy for differentiated thyroid carcinoma.
    Sherman SI
    Clin Oncol (R Coll Radiol); 2010 Aug; 22(6):464-8. PubMed ID: 20452757
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular targeted therapies for patients with refractory thyroid cancer.
    Chougnet C; Brassard M; Leboulleux S; Baudin E; Schlumberger M
    Clin Oncol (R Coll Radiol); 2010 Aug; 22(6):448-55. PubMed ID: 20554167
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers.
    Sherman SI
    J Clin Endocrinol Metab; 2009 May; 94(5):1493-9. PubMed ID: 19258410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer.
    Iñiguez-Ariza NM; Ryder MM; Hilger CR; Bible KC
    Thyroid; 2017 Jul; 27(7):923-927. PubMed ID: 28471306
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Failure of medullary carcinoma of the thyroid to respond to doxorubicin therapy.
    Husain M; Alsever RN; Lock JP; George WF; Katz FH
    Horm Res; 1978; 9(1):22-5. PubMed ID: 618781
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer.
    Takahashi S; Kiyota N; Yamazaki T; Chayahara N; Nakano K; Inagaki L; Toda K; Enokida T; Minami H; Imamura Y; Fukuda N; Sasaki T; Suzuki T; Ikezawa H; Dutcus CE; Tahara M
    Future Oncol; 2019 Mar; 15(7):717-726. PubMed ID: 30638399
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma.
    Shimaoka K; Schoenfeld DA; DeWys WD; Creech RH; DeConti R
    Cancer; 1985 Nov; 56(9):2155-60. PubMed ID: 3902203
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Expression of the MDR1 gene in five human cell lines of medullary thyroid cancer and reversion of the resistance to doxorubicine by ciclosporin A and verapamil].
    Massart C; Gibassier J; Lucas C; Pourquier P; Robert J
    Bull Cancer; 1996 Jan; 83(1):39-45. PubMed ID: 8672855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.